Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases - a longitudinal study. by Fischer, L. et al.
Fischer et al. Arthritis Research & Therapy  (2015) 17:151 
DOI 10.1186/s13075-015-0663-9RESEARCH ARTICLE Open AccessPneumococcal polysaccharide vaccination
in adults undergoing immunosuppressive
treatment for inflammatory diseases – a
longitudinal study
Lara Fischer1,2, Patricia Francis Gerstel1, Antoine Poncet3, Claire-Anne Siegrist4, Emmanuel Laffitte2, Cem Gabay5,
Joerg Dieter Seebach1 and Camillo Ribi1,6*Abstract
Introduction: Patients undergoing immunosuppressive therapy are at increased risk of infection. Community-
acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this
population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take
place before the start of immunosuppressive treatment. Often, however, the treatment cannot be delayed. Little is
known about the efficacy of pneumococcal vaccines during immunosuppressive treatment. The objectives of this
study were to determine the percentage of vaccine-naïve, immunosuppressed adults with inflammatory diseases
seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical
impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.
Methods: This observational study included patients 18 years of age and older who were receiving prednisone ≥20
mg/day or other immunosuppressive drugs. Exclusion criteria were PPV administration in the previous 5 years,
intravenous immunoglobulins and pregnancy. Serum immunoglobulin G (IgG) antibody levels against six
pneumococcal serotypes were measured. Seropositivity was defined as IgG of 0.5 μg/ml or greater for at least four
of six serotypes. Seronegative patients received PPV, and seropositive patients were included as a comparison
group. Vaccine response and tolerance were assessed after 4–8 weeks. Disease activity was evaluated on the basis
of the Physician Global Assessment scores. Serology was repeated after 1 year, and information on any kind of
infection needing medical attention was collected. Outcomes were the proportion of seropositivity and infections
between vaccinated and unvaccinated patients.
Results: Of 201 included patients, 35 received high-dose corticosteroids and 181 were given immunosuppressive
drugs. Baseline seronegativity in 60 (30 %) patients was associated with corticotherapy and lower total IgG. After
PPV, disease activity remained unchanged or decreased in 81 % of patients, and 87 % became seropositive. After 1
year, 67 % of vaccinated compared with 90 % of observed patients were seropositive (p < 0.001), whereas the rate
of infections did not differ between groups. Those still taking prednisone ≥10 mg/day tended to have poorer
serological responses and had significantly more infections.
Conclusions: PPV was safe and moderately effective based on serological response. Seropositivity to pneumococcal
antigens significantly reduced the risk of infections. Sustained high-dose corticosteroids were associated with poor
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Infections cause substantial morbidity and mortality
among patients with immune-mediated inflammatory
disorders [1, 2]. In rheumatoid arthritis (RA) and sys-
temic lupus erythematosus (SLE), pneumonia accounts
for up to 25 % of fatalities [3]. One risk factor for infec-
tion in these patients is the frequent use of immunosup-
pressive therapies. Prednisone has been associated with
pneumonia [4, 5], and cyclophosphamide, azathioprine
and newer biologic agents such as tumor necrosis factor
(TNF)-α blockers have been shown to confer an in-
creased risk of infection [6–9]. Another risk factor arises
from immune defects associated with the inflammatory
disorder itself [1, 10].
Guidelines recommend the administration of pneumo-
coccal vaccines to patients from receiving immunosup-
pressive treatment [11–14]. However, only a minority of
patients are vaccinated against Streptococcus pneumo-
niae [15, 16]. Several factors may account for this low
rate of vaccination. First, there are doubts concerning
the immunogenicity of vaccines in patients undergoing
immunosuppressive therapy [17, 18]. The suppression of
lymphocyte proliferation and function might control the
underlying condition but simultaneously lead to im-
paired antigen responses. Second, there is lack of proof
regarding the efficacy of pneumococcal polysaccharide
vaccine (PPV) in preventing invasive pneumococcal dis-
ease (IPD), pneumonia and mortality for patients with
chronic illnesses [19]. There are also concerns about the
duration of vaccine response in these patients. Indeed,
PPV is based solely on capsular polysaccharides, which
behave as T-cell-independent antigens and induce a lim-
ited humoral response without generation of memory B
cells. It has been shown that post-vaccine antibodies
wane faster in patients under immunosuppressive ther-
apies than in healthy individuals [20, 21]. Last, there
have been case reports of a causal relationship between
pneumococcal vaccination and the clinical onset or
flare-ups of immune-mediated inflammatory disorders,
in particular in autoinflammatory conditions [22]. How-
ever, several prospective studies have shown that pa-
tients may be immunized without exacerbation of the
underlying inflammatory disease [11, 23, 24]. There are
limited data on the utility of pneumococcal vaccines in
adult patients undergoing immunosuppressive therapy for
immune-mediated inflammatory disorders. A retrospect-
ive study in patients with RA treated with methotrexate
found a significantly lower incidence of pneumonia over
the previous 10 years in patients having received PPV
compared with those never vaccinated [25].
We conducted a prospective, single-center, observa-
tional study to address the following issues: What is the
proportion of seronegativity to S. pneumoniae in a popu-
lation of patients with immune-mediated inflammatorydisorders under immunosuppressive treatment not vac-
cinated with PPV in the previous 5 years? Are there fac-
tors associated with seronegativity to pneumococcal
antigens? Does immunization with PPV induce disease
flare-up? Does PPV elicit sufficient responses to pneumo-
coccal antigens under immunosuppressive therapy? How
do antibody levels to S. pneumoniae evolve over time in
patients vaccinated and observed?
We also wanted to assess the rate of clinically relevant
infection over the course of 1 year with respect to
pneumococcal serology and examine whether other fac-
tors were associated with a higher risk of infection.
Methods
Patients
We conducted an observational study in an outpatient set-
ting. Between November 2008 and October 2011, adult
patients followed at the University Hospital of Geneva
were screened to participate. Inclusion criteria were a
minimum age of 18 years, a diagnosis of immune-
mediated inflammatory disorder and ongoing treatment
with high-dose systemic corticosteroids (≥20 mg/day
for ≥1 month) and/or immunosuppressive drugs (classical
immunosuppressive drugs and/or biologic immunomodu-
latory agents). Exclusion criteria were vaccination with
PPV in the previous 5 years, previous treatment with
intravenous immunoglobulins and pregnancy. None of the
patients was exposed to previous conjugate pneumococcal
vaccine, which was limited to pediatric patients at the time
of the study. The study was approved by the local ethics
review board of the University Hospitals Geneva (Com-
mission cantonale d’éthique de la recherche), and all pa-
tients gave their written informed consent to participate.
Inclusion started in the Division of Clinical Immunology
as a pilot study and was then extended to the divisions of
rheumatology and dermatology.
Assessment
Patients were assessed at baseline, 4–8 weeks after
immunization and after 1 year. Clinical data included
the nature of the underlying diseases, type and duration
of immunomodulatory treatments, previous influenza
and pneumococcal vaccination, disease activity and in-
fections. Inflammatory disorders were categorized into
five groups: (1) RA and spondylarthropathies, (2) psoria-
sis and psoriatic arthritis, (3) connective tissue diseases,
(4) systemic vasculitis and (5) others. The last group in-
cluded patients with rare inflammatory diseases that
could not be classified into a larger group, such as bullous
skin diseases and autoinflammatory syndromes. Informa-
tion on previous vaccines was gathered by reviewing the
certificate of vaccination or, if that was not available, by
reviewing the clinical charts and by patient recall. Disease
activity was assessed by using the Physician Global
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from 0 to 3 (0 = inactive disease, 1 = low disease activity,
2 = active disease and 3 = very active disease). PGA was
scored at baseline, 4–8 weeks after immunization and at
the end of follow-up. Infections were defined as infectious
events needing medical attention, regardless of severity.
This information was collected retrospectively at baseline
and at the end of the study with a patient questionnaire
(patients were asked about symptoms, diagnosis and med-
icines prescribed) by reviewing the electronic medical re-
cords and by contacting the primary care physician when
needed. Safety aspects were based on assessment of dis-
ease activity 4–8 weeks after the immunization and oral
questioning about systemic vaccine reactions. Changes in
immunosuppressive treatment were assessed at the end of
follow-up. Serum was sampled at each assessment.
Pneumococcal serology
Baseline serologies were performed in real time to allow
decisions to be made regarding either vaccination or ob-
servation. Levels of specific immunoglobulin G (IgG)
antibody against three pneumococcal serotypes (14, 19F
and 23F) and three supplementary serotypes (1, 5, 7F or
9N, 11A and 17F) were determined by enzyme-linked
immunosorbent assay (ELISA) according to the World
Health Organization (WHO) consensus protocol [26],
which includes serum preadsorption with pneumococcal
cell wall- and serotype 22F polysaccharides and uses 89-SF
as a reference for antibody quantification. Supplementary
serotypes 1, 5 and 7F were replaced in 2011 by 9N, 11A
and 17F because the 13-valent conjugated vaccine had be-
come available, although it was not used in this study. Pa-
tients with specific IgG levels ≥0.5 μg/ml to at least four of
the six tested serotypes were empirically considered
as having sufficient antibodies, as not requiring
immunization and defined as “seropositive.” Positive vac-
cine response was defined by reaching seropositivity 4–8
weeks after PPV. Patients having received PPV off-protocol
or treated with B-cell-depleting therapies within 6 months
of the vaccine were not assessed for vaccine response.
Total serum immunoglobulins
Serum IgG, IgA and IgM were measured with an
IMMAGE nephelometer (Beckman Coulter, Nyon,
Switzerland) and specific anti-sera against heavy chains γ,
α and μ, respectively. Normal values were established with
sera of healthy blood donors.
Vaccination procedure
Seronegative patients were offered the 23-valent PPV
(PNEUMOVAX 23; Merck, West Point, PA, USA),
which was the sole pneumococcal vaccine licensed for
adults at the time of the study. PPV contains 25 μg of
pneumococcal capsular polysaccharides of 23 serotypes(1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,
17F, 18C, 19A, 19F, 20, 22F, 23F and 33F) [27]. The vac-
cine was given intramuscularly.
Objectives
The primary study objectives were to compare the pro-
portion of seropositives at baseline and after 1 year in
vaccinated and observed patients. The secondary objec-
tives were the assessment of changes in disease activity
before and after immunization and to compare the rate
of infections in the respective groups.
Statistical analysis
Data were analyzed using the STATA statistical software
package (version 13; StataCorp, College Station, TX,
USA). Normally distributed data were described by
means with standard deviations and skewed data by me-
dians and interquartile ranges (IQRs). Non-parametric
tests for significance (Wilcoxon rank-sum test for con-
tinuous data, χ2 test or Fisher’s exact test for categorical
data) were conducted where appropriate. As IgG titers
for individual serotypes relied on several real-time as-
sessments and had censored values in the lower and
upper ranges, we used reverse cumulative distribution
curves [28] and the paired Prentice–Wilcoxon test [29].
Determinants for serological response at baseline were
assessed with logistic regression analysis and for individual
serotypes using a lognormal model. Predictors of vaccine
response and infections were assessed using univariate
log-binomial regression models. A p-value less than 0.05
was considered statistically significant in all analyses.
Results
Two hundred one patients were included in the study
(Fig. 1). Sixty patients met the criteria for PPV adminis-
tration. Four patients refused vaccination. Fifty-seven re-
ceived PPV and were assessed for tolerance, including
one patient in the observation group who received the
vaccine off-protocol. Vaccine response was assessed in
53 patients. One hundred ninety (95 %) patients were
followed for a median (IQR) of 384 (364–421) days. Eleven
patients could not be assessed: six moved away and five
refused the follow-up visit, with four of them contacted by
telephone and questioned for infectious events. Long-term
serological response was assessed in 184 patients, of
whom 49 had been vaccinated and 135 observed.
Baseline characteristics
The demographics, baseline characteristics and treat-
ment of the 201 included patients are shown in Table 1.
One hundred eighty-one patients (90 %) were treated with
immunosuppressive drugs, and twenty patients (10 %) had
high-dose corticosteroids only. Systemic corticosteroids
were used in 96 % of patients with vasculitis and in 4 % of
Fig. 1 Flowchart of the study. PPV pneumococcal polysaccharide vaccine
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used in 75 % of patients with vasculitis and 35 % with
psoriasis (p = 0.001). Biologic immunosuppressants were
used as monotherapy in 34 patients with psoriasis (65 %),
20 with RA and/or spondylarthropathies (36 %), 4 with
connective tissue diseases and miscellaneous conditions,
and none with vasculitis. Seventeen patients (9 %) had re-
ceived rituximab at a median (IQR) of 337 (14–1652) days
before inclusion. One hundred seventeen patients (60 %)
received in 2009 a split seasonal influenza vaccine, one
hundred five (54 %) were given an AS03-adjuvanted pan-
demic influenza vaccine and one hundred twelve (57 %)
received a split seasonal influenza vaccine in 2010. Ac-
cording to enrollment criteria, none of the patients had re-
ceived pneumococcal vaccines in the previous 5 years. Of
the 190 patients in which written information on previous
immunizations was available, none had ever received a
pneumococcal vaccine.
Baseline serology
At baseline, 60 patients (30 %) were defined as seronega-
tive for S. pneumoniae. Seronegativity was significantly
associated with the use of systemic corticosteroids and
lower total serum IgG levels (Table 1). Multivariate re-
gression analysis confirmed the association of low levels
of serum IgG against individual pneumococcal serotypeswith systemic corticosteroids, as shown in Table 2. Other
factors associated with a decrease in pneumococcus-
specific IgG were age ≥65 years, active disease (PGA
score ≥2) and low total serum Ig. In seronegative pa-
tients, infectious events had occurred during the pre-
ceding 3 months in 19 (32 %) of 60 compared with 18
(13 %) of 141 seropositives (p = 0.03) (Table 3).
Immunization with pneumococcal polysaccharide vaccine
Fifty-seven patients received PPV. There was no sys-
temic reaction to the vaccine. Mean disease activity ac-
cording to the PGA score was 1.23 ± 0.61 before
vaccination and 1.06 ± 0.69 1 month after immunization
(p = NS). PGA scores did not change in 34 patients, de-
creased in 13 and increased in 6. Of the 53 patients
assessed 4–8 weeks after PPV, 46 (87 %) reached seroposi-
tive thresholds (Fig. 2). Non-responders had lower IgM
levels (median IgM of 0.66 g/L compared with 0.9 g/L in
responders; p = 0.044) and tended to have higher cortico-
steroid dosages (daily prednisone equivalent ≥20 mg in
57 % compared with 22 % of responders; p = 0.07).
One-year follow-up
Disease activity according to PGA score decreased from
1.12±0.77 at baseline to 0.93±0.76 (p = 0.004) in the obser-
vation group and from 1.2±0.56 to 0.91±0.88 (p = 0.025)
Table 1 Demographic, disease and treatment characteristics of 201 patients at inclusion and comparison between groups according
to baseline pneumococcal serology
Characteristics All (N = 201) Vaccination groupa (n = 60) Observation groupb (n = 141) p-Value
Median age (IQR), yr 53.9 (43.3–65.7) 58.6 (37.0–71.9) 53.1 (42.6–61.9) NS
Male/female, n 84/117 22/38 62/79 NS
Disease type
Psoriasis, n (%) 52 (26) 8 (13) 44 (31) 0.03
Rheumatoid arthritis, n (%) 41 (20) 13 (22) 28 (20) NS
Spondylarthropathies, n (%) 15 (7) 4 (7) 11 (8) NS
Connective tissue diseases, n (%) 31 (15)c 11 (18) 20 (14) NS
Systemic vasculitis, n (%) 24 (12)d 12 (20) 12 (9) 0.03
Miscellaneous inflammatory conditions, n (%) 38 (19)e 12 (20) 26 (18) NS
Disease activity according to PGA 0.019
Inactive, n (%) 28 (14) 2 (3) 26 (18)
Moderately active, n (%) 120 (60) 44 (73) 76 (54)
Active, n (%) 44 (22) 12 (20) 32 (23)
Very active, n (%) 9 (5) 2 (3) 7 (5)
Treatment
Systemic corticosteroids, n (%) 91 (45) 41 (68) 50 (36) <0.001
Daily prednisone dose, median (IQR), mg 10 (5–30) 10 (5–30) 10 (7.5–27.5) NS
Prednisone ≥20 mg/day, n (%) 35 (17) 16 (27) 19 (14) 0.02
Immunosuppressant, n (%) 181 (90)f 50 (83) 131 (93) NS
Other DMARDs, n (%) 25 (12)g 10 (17) 15 (11) NS
Previous rituximab treatment, n (%) 17 (9) 5 (8) 12 (9) NS
Treatment duration, median (IQR), yr 2 (0–6) 2 (0–6) 2 (0–6) NS
Total serum IgG, median (IQR), g/L 10.8 (8.6–13.2) 9.0 (7.5–12.1) 11.2 (9–13.4) 0.003
Total serum IgA, median (IQR), g/L 2.1 (1.6–3.1) 2.1 (1.3–3.0) 2.3 (1.6–3.2) NS
Total serum IgM, median (IQR), g/L 0.9 (0.7–1.4) 0.8 (0.6–1.2) 1.0 (0.7–1.4) NS
Abbreviations: DMARD disease-modifying anti-rheumatic drug, Ig immunoglobulin, IQR interquartile range, NS not significant, PGA Physician Global Assessment.
p-Values were obtained by χ2 and Mann–Whitney U tests
aIgG ≥0.5 μg/ml for fewer than four of six serotypes
bIgG ≥0.5 μg/ml for four or more of six serotypes
cSystemic lupus erythematosus (n = 13), dermatomyositis (n = 5), mixed connective tissue disease (n = 4), polymyositis (n = 3), anti-synthetase syndrome (n = 3),
undifferentiated connective tissue disease (n = 2), systemic sclerosis (n = 1)
dGiant cell arteritis (n = 7), granulomatosis with polyangiitis (n = 6), primary angiitis of the central nervous system (n = 5), microscopic polyangiitis (n = 4),
Takayasu arteritis (n = 1), polyarteritis nodosa (n = 1)
ePemphigus vulgaris (n = 7), adult-onset Still disease (n = 6), bullous pemphigoid (n = 5), Behçet disease (n = 4), orbital pseudotumor (n = 3), unspecified inflammatory
disorders (n = 3), autoinflammatory disorders (n = 2), cicatricial pemphigoid (n = 2), uveitis (n = 2), retroperitoneal fibrosis (n = 2), polymyalgia rheumatica (n = 1), aortitis
(n = 1)
fMethotrexate (n = 60), adalimumab (n = 24), infliximab (n = 24), azathioprine (n = 23), mycophenolate mofetil (n = 22), mycophenolic acid (n = 3), tocilizumab
(n = 19), leflunomide (n = 11), etanercept (n = 7), ustekinumab (n = 7), golimumab (n = 4), cyclophosphamide (n = 2), anakinra (n = 2), abatacept (n = 2),
rituximab in the preceding 6 months (n = 2), chlorambucil (n = 1), ciclosporin A (n = 1), tacrolimus (n = 1), certolizumab (n = 1). More than one
immunosuppressive agent was used in 37 patients (18 %)
gHydroxychloroquine (n = 16), sulfasalazine (n = 7), colchicine (n = 2), dapsone (n = 2). More than one non-immunosuppressive DMARD was used in two patients
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formed within a median (IQR) of 383 (364–421) days in
patients observed and 369 (342–392) days in patients vac-
cinated. Within the observation group, 13 (10 %) of 135
had become seronegative to S. pneumoniae compared
with 16 (33 %) of 49 immunized patients (p < 0.001). Of
the 42 patients seropositive after PPV, 9 (21 %) had be-
come seronegative. The decline in antibody titers to sero-
types 14, 19 and 23F after 1 year in vaccinated patientscompared with those observed is shown in Fig. 3. Of the
16 seronegative patients 1 year after PPV, 12 (75 %) were
still taking corticosteroids. Four of them had prednisone
doses ≥10 mg/day both at inclusion and at the end of
follow-up. In comparison, 16 (53 %) of the seropositive pa-
tients were treated with corticosteroids, with 2 having
prednisone doses ≥10 mg/day at both study start and end
(p = 0.086). There was no difference regarding the type of
immunosuppressant used.
Table 2 Multivariate regression analysis of factors associated with levels of serum IgG against pneumococcal serotypes 14, 19 and
23F in 201 patients at inclusion
Serotype 14 Serotype 19 Serotype 23F
OR 95 % CI p-Value OR 95 % CI p-Value OR 95 % CI p-Value
CTD vs. RA and SpA 2.33 1.15–4.71 0.019 1.11 0.68–1.81 NS 0.73 0.41–1.30 NS
Vasculitis vs. RA and SpA 1.30 0.59–2.87 NS 0.92 0.53–1.61 NS 0.84 0.44–1.61 NS
Other disease vs. RA and SpA 1.93 1.00–3.69 0.048 1.45 0.92–2.28 NS 1.62 0.97–2.71 0.067
Psoriasis vs. RA and SpA 1.60 0.91–2.81 NS 1.65 1.09–2.51 0.018 1.16 0.74–1.81 NS
Active diseasea – – NS – – NS 0.67 0.46–0.97 0.035
Systemic corticosteroids 0.46 0.26–0.81 0.007 0.69 0.46–1.03 0.066 0.62 0.39–0.98 0.039
Older ageb – – NS 0.58 0.41–0.81 0.002 0.62 0.42–0.92 0.018
Low total serum IgAc – – NS – – NS 0.67 0.48–0.93 0.017
Low total serum IgMd – – NS 0.77 0.57–1.04 NS 0.76 0.55–1.05 0.096
Abbreviations: 95 % CI 95 % confidence interval, CTD connective tissue disease, Ig immunoglobulin, NS not significant, OR odds ratio, RA rheumatoid arthritis, SpA
spondylarthritis. The variables used in this model were age at baseline serology, disease category; global disease activity according to the Physician Global
Assessment score; use of systemic corticosteroids; use of immunosuppressive agents (cytotoxic drugs, methotrexate, tumor necrosis factor-α-blocking agents,
anti-cytokine agents in general, monotherapy with biologic, or combination therapy); duration of immunosuppression; and total serum IgG, IgA and IgM
aPhysician Global Assessment: very active and active versus low activity and inactive disease
bAge ≥65 yr versus <65 yr
cSerum IgA <2 g/L vs. ≥2 g/L
dSerum IgM <1 g/L vs. ≥1 g/L
Table 3 Infectious events and immunosuppressive treatment in 201 patients with inflammatory diseases, attributed to an
observation and vaccination group according to pneumococcal serology at baseline
Baseline Follow-up
Observed patients Vaccination groupa
(n = 60)
Observation groupb
(n = 141)
All
(N = 201)
Vaccination groupa
(n = 56)
Observation groupb
(n = 138)
All
(n = 194)
Patients with infections, n (%)c 19 (32) 18 (13) 37 (18) 22 (39) 54 (39) 76 (39)
Infectious events, n 22 19 41 32 77 109
Localization/type of infection, n (%)
Upper respiratory tract 10 (45)d 9 (47) 19 (46) 12 (38) 45 (58) 57 (52)
Lower respiratory tract 2 (9) 2 (11) 4 (10) 7 (22) 4 (5) 11 (10)
Urinary tract 3 (14) 1 (5) 4 (10) 5 (16) 16 (21) 21 (19)
Gastrointestinal 0 (0) 2 (11) 2 (5) 4 (13) 3 (4) 7 (6)
Shingles 1 (5) 0 (0) 1 (2) 1 (3) 3 (4) 4 (4)
Tuberculosise 0 (0) 0 (0) 0 1 (3) 1 (1) 2 (2)
Skin infection 2 (9) 1 (5) 3 (7) 2 (6) 1 (1) 3 (3)
Otherf or not specified 4 (18) 4 (21) 8 (20) 0 (0) 4 (5) 4 (4)
Immunosuppressant, n (%) 50 (83) 131 (93) 181/201
(90)
38 (70) 118 (87) 156/190
(82)
Systemic corticosteroids, n (%) 41 (68) 50 (36) 91/201
(45)
28 (56) 43 (32) 71/185
(38)
Prednisone ≥10 mg/day at study start
and end
– – – 5 (9) 12 (9) 17/194 (9)
aImmunoglobulin G (IgG) ≥0.5 μg/ml for fewer than four of six serotypes
bIgG ≥0.5 μg/ml for four or more of six serotypes
cInfectious events needing medical attention, at baseline, in the 3 months preceding inclusion and during the median (interquartile range) follow-up period of
384 (364–421) days
dConfirmed influenza A H1N1/09 in two patients, both of whom did not receive the pandemic influenza vaccine
eOne case of reactivation of latent tuberculosis with intestinal involvement and one case of newly diagnosed latent tuberculosis
fDental infection (n = 1), Chagas disease (n = 1), esophageal candidiasis (n = 1)
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Fig. 2 Serological response to vaccine serotypes 14, 19 and 23F at baseline and after 23-valent pneumococcal polysaccharide vaccine in the 53
immunized patients. Reverse cumulative distribution curves of specific serum immunoglobulin G to serotypes 14, 19 and 23F in the 53 immunized
patients before 23-valent polysaccharide pneumococcal vaccine administration (thin blue lines) and 4–8 weeks after immunization (bold blue lines).
Baseline serology of the 141 vaccine-naive patients in the observation group is shown for comparison (dotted red lines). Reverse cumulative
distribution function takes into account censored values obtained by real-time enzyme-linked immunosorbent assay [28]
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54 (39 %) of 138 patients observed and in 22 (39 %) of 56
of those in the vaccination group (Table 3). There was no
documented pneumococcal infection and no event sug-
gestive of IPD. Severe infections included one case of intes-
tinal tuberculosis and one case of legionellosis, both in
patients treated with TNF-α-blocking agents (one in the
observation group and the other in the vaccination group).
When taking into account pneumococcal serology at
the end of follow-up, regardless of immunization, infec-
tions had occurred in 54 (34.4 %) of 157 seropositive pa-
tients compared with 19 (59.4 %) of 32 in seronegative
patients (p = 0.008). In patients who received PPV, over-
all infections occurred in 12 (36 %) of 34 of those sero-
positive, compared with 9 (60 %) of those seronegative, at
1 year (p = NS). Infections of the airways potentially pre-
vented by the vaccine were reported in 8 patients (24 %)
seropositive, compared with 8 patients (50 %) who were
seronegative, 1 year after PPV (p = 0.07).
Infections occurred in 14 (82 %) of 17 patients taking
prednisone ≥10 mg/day at both study start and end,
compared with 62 (35 %) of 122 patients without sus-
tained high-dose prednisone or without corticosteroids
(p < 0.001). Besides regular prednisone intake of ≥10
mg/day, no other predictors of infections were found
(Table 4).Discussion
Pneumococcal vaccines are infrequently administered to
patients with immune-mediated inflammatory disorders,
despite an associated increased risk of pneumonia and
IPD. This is likely due to concerns about vaccine safety
and efficacy. Recommendations regarding pneumococcal
vaccination rely on weak evidence, and there are doubts
about the efficacy of polysaccharide vaccines in adults
undergoing immunosuppressive treatment. In this
prospective study, we recruited 201 adults with
immune-mediated inflammatory disorders undergoing
immunosuppressive treatment, to whom no pneumococ-
cal vaccine had been administered in the previous 5
years. Most if not all of these patients had never been
immunized against S. pneumoniae. Less than 60 % of pa-
tients had received influenza vaccines, despite these vac-
cines’ being actively promoted in this risk group,
confirming the low compliance with vaccine guidelines.
We found that 70 % of patients had antibodies to the
six S. pneumoniae serotypes assessed. Seronegative pa-
tients had more active disease and accordingly were
more often treated with systemic corticosteroids. They
also had lower total serum IgG levels. Patients with sys-
temic vasculitis were more often seronegative, in con-
trast to those with psoriasis. This finding is probably due
to predominant use of corticosteroids and cytotoxic
Fig. 3 Evolution of serology to vaccine serotypes 14, 19 and 23F in 49 patients immunized with the 23-valent polysaccharide pneumococcal vaccine
compared with 135 patients observed after 4–8 weeks and after 1 year. Reverse cumulative distribution curves of specific serum immunoglobulin G (IgG)
against serotypes 14, 19 and 23F in patients immunized 4–8 weeks after vaccine (thin blue lines) and after 1 year (bold blue lines) compared with patients
observed after 1 year (dotted red lines). Reverse cumulative distribution function takes into account censored values obtained by real-time enzyme-linked
immunosorbent assay [28]. Median (95 % confidence interval) specific IgG titers to pneumococcal serotype 14 decreased from 2.5 (1.2–4.1) μg/ml 4–8
weeks after immunization to 1.1 (0.8–3.0) μg/ml after 1 year (p = 0.001 by from paired Prentice–Wilcoxon test for censored paired data), to serotype 19 from
2.3 (1.7–3.3) to 1.5 (1.2–2.1) μg/ml (p = 0.009) and to serotype 23F from 0.7 (0.5–1.1) to 0.5 (0.4–0.7) μg/ml (p = 0.005). In patients observed, median (95 %
confidence interval) IgG values after 1 year were 2.5 (2.1–3.4) μg/ml to serotype 14, 3.1 (2.5–4.2) μg/ml to serotype 19 and 0.8 (0.6–1.0) to serotype 23F
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psoriasis and arthritis, who were frequently treated with
TNF-α-blocking agents alone. Others have assessed pre-
vaccination antibody levels to S. pneumoniae in patients
with RA and SLE without noticing significant differences
according to disease or immunosuppressive treatment
[30, 31]. We also found significantly lower prevaccina-
tion antibody titers to serotypes 19 and 23F in patients
older than 65 years of age. Other studies have addressed
serological responses in the elderly, which has led to
recommendations to give persons over 65 years of age
PPV [12, 13].Table 4 Predictors of reported infections during the 1-year follow-p
an inflammatory disease
Overall infections
RR 95 % CI
Sustained systemic corticosteroidsa 2.35 1.75–3.17
Active diseaseb 1.13 0.77–1.66
Age at inclusion ≥65 yr vs. <65 yr 0.99 0.66–1.48
Abbreviations: 95 % CI 95 % confidence interval, RR univariate relative risk
aPrednisone equivalent ≥10 mg/day at inclusion and at the end of follow-up vs. <1
bPhysician Global Assessment score 2 and 3 (active and very active disease) vs. 0 anPPV was well tolerated, with no reports of systemic reac-
tion. Only a few patients had an increase in disease activity
after vaccination. Other prospective studies, including our
previous work on a similar population, have shown that
vaccines does not usually trigger disease flares in patients
with chronic inflammatory diseases [11, 23, 24, 32, 33].
Serological responses assessed shortly after PPV were
good, with 87 % of the vaccinated patients reaching
seropositive thresholds. Non-responders had higher cor-
ticosteroid doses. Others have linked diverse immuno-
suppressants to reduced vaccine response. Elkayam et al.
showed that in patients with RA and SLE treated witheriod in 194 patients treated with immunosuppressive drugs for
Infections of the airways
p-Value RR 95 % CI p-Value
<0.001 2.43 1.56–3.80 <0.001
0.534 1.51 0.97–2.35 0.069
0.947 0.87 0.51–1.48 0.604
0 mg/day
d 1 (inactive or moderately active disease) at inclusion
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one-third of patients vaccinated with PPV had an insuffi-
cient response: 14 (33.3 %) of 43 patients with RA and 5
(20.8 %) of 24 patients with SLE responded to 0 or 1 of
7 vaccine serotypes assessed [30]. In particular, combin-
ation treatment with methotrexate and TNF-α-blocking
agents resulted in poor vaccine responses [23, 31, 34–36],
whereas this was not seen in patients treated solely with
TNF-α-blocking agents [24, 31, 34, 37, 38]. In our patients,
methotrexate was not associated with poor response to
PPV, nor were there other predictors of short-term vaccine
response besides corticosteroids, which is possibly due to
the small number of immunized patients in our sample. In
healthy individuals, antibody levels toward PPV serotypes
remain high for at least 5 to 10 years postvaccination [39].
A small study on 19 patients with SLE showed a decrease
in antibody levels below the protective level in 42 % of pa-
tients 3 years after PPV [20]. A more rapid decline was
shown in patients with RA undergoing immunosuppres-
sive treatment [21]. In our study, 90 % of the initially sero-
positive patients maintained specific antibody titers over
the course of 1 year without vaccination. In contrast, those
patients initially seronegative and who responded to PPV
had a significant decrease in antibody titers over the next
year. This rapid loss of serological response was also asso-
ciated with corticosteroids.
There were no differences in the rate of clinical infec-
tions in patients vaccinated and observed during follow-
up. No pneumococcal infection was documented. Overall,
infectious events were, however, associated with seronega-
tivity. This suggests that pneumococcal serology is a
marker of the degree of immunosuppression in our popu-
lation, with those treated with high-dose corticosteroids
having lower titers of pneumococcal IgG. Sustained corti-
cotherapy was also associated with an increased rate of in-
fection, as shown by others [5, 25]. This poses a clinical
dilemma. On the one hand, although PPV seems safe in
patients with active disease, concomitant treatment with
corticosteroids may hamper vaccine response. On the
other hand, these patients are also at greatest risk for in-
fections. With the serological results shown, one would be
tempted to postpone PPV until corticosteroids have been
lowered. However, those who stayed seropositive 1 year
after PPV tended to have fewer respiratory infections than
seronegative patients (p = 0.07). Thus, some of these pa-
tients may benefit from PPV in the short term through a
reduction of non-invasive pneumococcal infections. Con-
jugated pneumococcal vaccines are currently being stud-
ied in adults with immunosuppression and may increase
the likelihood of sustained serological response.
One of the greatest difficulties in the evaluation of vac-
cine response is to determine whether serum antibody
titers correlate with clinical protection. Functional anti-
bodies measured by opsonophagocytosis may be morerelevant for protection against pneumococcal infections
than antibodies assessed by ELISA. Limited resources
did not allow us to include either this assay or the ana-
lysis of antibodies to more than six serotypes. Another
possible limitation of the present study is our definition
of serological response. The WHO considers levels of
IgG antibodies to individual pneumococcal serotypes of
0.35 μg/ml or greater as protective against IPD [40].
However, serotype-specific antibody levels correlating
with protection differ for each serotype and each clinical
endpoint, as well as in various populations. Healthy indi-
viduals are expected to respond to at least half of the
evaluated serotypes following vaccination [37]. We
therefore chose to define seropositivity and vaccine re-
sponse as a specific IgG level greater than or equal to
0.5 μg/ml to at least four of the six tested serotypes, be-
ing aware that these are empirical criteria. The absence
of documented pneumococcal infections may be seen as
another limitation of the study, but the expected inci-
dence of pneumococcal disease in this population was
low, particularly over the observation period of 1 year.
In addition, pneumococcal infections can be somewhat
difficult to prove, as cultures or urinary pneumococcal
antigen testing are not always performed.
The strength of our study lies in the combination of
serologies and clinical assessment, in particular regard-
ing disease activity, immunosuppressive treatment and
infectious complications. Patients were prospectively
followed, and only a few were lost to follow-up by the
end of the study. We did not randomize patients at in-
clusion to receive PPV, which would have been uneth-
ical. Only seronegative patients received the vaccine,
which we thought would be those most in need of pro-
tection. The heterogeneity in immune-mediated inflam-
matory disorders and treatments may be seen as a
limitation, but it reflects a real-life setting.
Conclusions
This study underlines the good tolerance of pneumococ-
cal immunization in immunosuppressed adults with
immune-mediated inflammatory diseases, as well as the
limited immunogenicity of PPV, which elicits very transi-
ent responses. In our patients, low serum IgG to pneumo-
coccal antigens reflected the severity of the underlying
disease and the degree of immunosuppression. Systemic
corticosteroids in particular were associated with poor
serological response and an increase in various infectious
events. This study adds evidence to the poor performance
of PPV in adults on immunosuppressive medication and
should motivate the development of newer vaccine strat-
egies in this particular setting. Studies are needed to assess
whether the conjugate vaccine is well tolerated and leads
to effective protection from pneumococcal invasive dis-
ease in this fragile population.
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